Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC (GSK)

153
Delayed Quote. Delayed London Stock Exchange - 10/24 11:35:28 am
1415.5 GBp   +0.25%
11h ago Five Prime Therapeutics Expands Collaboration With Glaxo
11h ago NUMIS : BESTOF the BROKERS
1d ago GLAXOSMITHKLINE : DIRECTOR DEALINGS: Glaxo Chief Executive Exercises Option..
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Sales27 38726 43126 50523 40424 93825 800
Operating income (EBITDA)10 2319 4158 8837 8638 0488 482
Operating profit (EBIT)8 5548 3308 0156 4946 7897 136
Pre-Tax Profit (EBT)7 6986 6926 6474 8265 4896 038
Net income5 2614 5655 6283 5673 5914 029
EPS (PNC)10391,511172,488,285,0
Dividend per Share (PNC)70,074,078,080,481,883,7
Yield4,96%5,24%5,52%5,70%5,79%5,93%
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Debt9 00314 03712 64512 63810 88711 040
Finance------
Operating income (EBITDA)10 2319 4158 8837 8638 0488 482
Leverage
(Debt/EBITDA)
0,88x1,49x1,42x1,61x1,35x1,30x
Capital Expenditure9231 0511 1881 4361 4881 507
Book Value Per Share (BVPS)162 PNC120 PNC146 PNC73,6 PNC15,4 PNC4,16 PNC
Cash Flow per Share124 PNC87,7 PNC149 PNC108 PNC115 PNC137 PNC
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2014 Thomson Reuters
Advertisement
Financial Ratios

Size 2014e 2015e
Capitalization 68 479 M GBP -
Entreprise Value (EV) 81 117 M GBP 79 365 M GBP
Valuation 2014e 2015e
PER (Price / EPS) 19,5x 16,0x
Capitalization / Revenue 2,93x 2,75x
EV / Revenue 3,47x 3,18x
EV / EBITDA 10,3x 9,86x
Yield (DPS / Price) 5,70% 5,79%
Profitability 2014e 2015e
Operating Margin (EBIT / Sales) 27,7% 27,2%
operating Leverage (Delta EBIT / Delta Sales) -1,62x 0,69x
Net Margin (Net Profit / Revenue) 15,2% 14,4%
ROA (Net Profit / Asset) 7,60% 7,85%
ROE (Net Profit / Equities) 60,2% 70,0%
Rate of Dividend 111% 92,8%
Balance Sheet Analysis 2014e 2015e
CAPEX / Sales   6,14% 5,97%
Cash Flow / Sales (Taux d'autofinancement) 22,4% 22,3%
Capital Intensity (Assets / Sales) 2,01x 1,83x
Financial Leverage (Net Debt / EBITDA) 1,61x 1,35x
Price Earning Ratio
EPS & Dividend
Dynamic quotes  
ON
| OFF